Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Tiantan Biological Products Corp Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Beijing Tiantan Biological Products's Operating Margin % or its related term are showing as below:
SHSE:600161'
s Operating Margin % Range Over the Past 10 Years
Min: 23.7 Med: 31.22 Max: 41.8
Current: 28.21
SHSE:600161's Operating Margin % is ranked better than 92.65% of 939
companies
in the Biotechnology industry
Industry Median: -86.33
vs SHSE:600161: 28.21
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Beijing Tiantan Biological Products Operating Margin % Related Terms
Beijing Tiantan Biological Products Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600161 vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Beijing Tiantan Biological Products's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tiantan Biological Products Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Tiantan Biological Products's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Beijing Tiantan Biological Products's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tiantan Biological Products (SHSE:600161) has a Operating Margin % of 18.82% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Beijing Tiantan Biological Products and its competitors. This is 40% below median its historical median of 31.22. Over the past decade, Beijing Tiantan Biological Products' Operating Margin % has ranged from 23.70 to 41.80. According to the industry distribution chart, Beijing Tiantan Biological Products ranks #69 out of 939 companies in the Biotechnology industry, placing it in the top 7.3%.
Is Beijing Tiantan Biological Products' Operating Margin % too high?
Beijing Tiantan Biological Products' current Operating Margin % of 18.82% is 40% below median its 10-year median of 31.22. Over the past 10 years, this metric has ranged from a low of 23.70 to a high of 41.80. Based on the distribution chart, Beijing Tiantan Biological Products ranks #69 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Tiantan Biological Products has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tiantan Biological Products' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Tiantan Biological Products ranks #69 out of 939 companies for Operating Margin %. This places Beijing Tiantan Biological Products in the top 7% of its industry — outperforming the majority of peers. Historically, Beijing Tiantan Biological Products' own Operating Margin % has ranged from 23.70 to 41.80 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Beijing Tiantan Biological Products and its competitors. Beijing Tiantan Biological Products's current Operating Margin % is 18.82%, which is 40% below median its own 10-year median of 31.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tiantan Biological Products stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products (SHSE:600161) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥23.94, compared to a current price of ¥12.95 — trading 45.9% below its estimated fair value. The current Operating Margin % is 18.82%, which is 40% below median its 10-year median of 31.22. Beijing Tiantan Biological Products' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Beijing Tiantan Biological Products (SHSE:600161), the current Operating Margin % is 18.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tiantan Biological Products (SHSE:600161) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products stock appears to be undervalued.
The current stock price of ¥12.95 is trading 45.9% below its estimated GF Value™ of ¥23.94.
GuruFocus considers Beijing Tiantan Biological Products to be Significantly Undervalued.
Key valuation signals for SHSE:600161:
Operating Margin %: 18.82% (40% below median its 10-year median of 31.22)
GF Value™: ¥23.94 vs. price of ¥12.95 (45.9% below fair value)
No single metric tells the full story. See the SHSE:600161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tiantan Biological Products Business Description
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
75GF Score
Get the complete analysis for SHSE:600161
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600161 has been successfully added to your 
